Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
PolarityTE, Inc. was a biotechnology company primarily focused on researching, developing, and commercializing regenerative tissue products. Its flagship product candidate was SkinTE, a patient-derived, autologous, homologous skin construct intended for the repair, reconstruction, replacement, or supplementation of skin in patients with acute or chronic wounds. The company aimed to revolutionize skin regeneration by enabling the growth of full-thickness skin with all its layers and appendages. PolarityTE filed for Chapter 7 bankruptcy in August 2023, leading to the cessation of its operations and liquidation of assets.
The headquarters served as the central hub for all corporate functions, including administration, finance, investor relations, clinical operations, and research and development activities for its regenerative medicine pipeline.
The facility housed corporate offices and specialized laboratory spaces equipped for biotechnology research, tissue engineering, and pre-clinical development.
During its operational years, PolarityTE likely fostered a work culture centered on scientific innovation, collaboration, and a strong focus on addressing unmet medical needs in wound care. As a clinical-stage biotech, the environment would have been dynamic and milestone-driven.
The Salt Lake City headquarters was critical for PolarityTE's entire operational lifecycle, from pioneering its core technology to managing clinical trials and corporate strategy before its eventual bankruptcy.
PolarityTE's operations, including research, development, and clinical trials, were primarily concentrated within the United States. While its product ambitions were global, the company did not maintain a significant physical international office presence. Its focus was on gaining FDA approval in the U.S. market first.
123 N. Wright Brothers Drive
Salt Lake City
Utah
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, PolarityTE' leadership includes:
PolarityTE has been backed by several prominent investors over the years, including:
In the 12-18 months leading up to its Chapter 7 bankruptcy filing in August 2023, PolarityTE faced significant operational and financial challenges. This period culminated in the cessation of operations and the departure of its remaining executive team. There were no significant executive hires during this final phase.
Discover the tools PolarityTE uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, PolarityTE likely used common corporate email address formats. As the company has ceased operations and its domain is inactive, these email addresses are no longer functional.
[first_initial][last]@polarityte.com (e.g., jdoe@polarityte.com) or [first].[last]@polarityte.com (e.g., jane.doe@polarityte.com)
Format
example@polarityte.com (inactive)
Example
0%
Success rate
Bloomberg Law • August 18, 2023
PolarityTE Inc. filed for Chapter 7 bankruptcy in the District of Utah, indicating its intent to liquidate assets and cease all operations after facing prolonged financial difficulties and challenges in bringing its regenerative tissue products to market....more
SEC Filing / Company Press Release (via various news outlets) • June 27, 2023
PolarityTE, trading under the ticker CURI, announced it received a determination letter from Nasdaq stating that its common stock would be delisted from The Nasdaq Stock Market due to non-compliance with continued listing requirements. Trading was suspended, and the stock later moved to OTC markets before the bankruptcy....more
PR Newswire • January 10, 2023
PolarityTE provided an update on its business activities and strategic outlook for 2023, emphasizing its focus on submitting an Investigational New Drug (IND) application for its SkinTE product and continuing efforts to secure necessary funding for its clinical development programs, while acknowledging ongoing financial challenges....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including PolarityTE, are just a search away.